Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
20 June, 2018 20:27 IST
Cipla, Unitaid enter into landmark deal to lower price of HIV drug
Source: IRIS | 08 Jun, 2018, 05.07PM
Comments  |  Post Comment

Unitaid and Indian drug manufacturer Cipla struck a landmark agreement today that will lower the price of the first combination therapy (containing co-trimoxazole, isoniazid and vitamin B6) that prevents opportunistic infections in people living with HIV.

The HIV virus can weaken the immune system, increasing the risk of dangerous infection by bacteria and viruses.

Under this agreement, Cipla will reduce the ceiling price of the medicine by more than 30 percent from USD 3 to USD 1.99 per person, per month, for all public-sector procurers in low- and middle-income countries. The price of the product is expected to come down more as governments and international funding bodies procure larger quantities for their HIV treatment programmes.

Shares of the company gained Rs 18, or 3.33%, to settle at Rs 558.25. The total volume of shares traded was 204,043 at the BSE (Friday).





Cipla Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
BHEL wins Rs 10 bn orders for emission control equipment - 20-Jun-2018 13:38
Tata Comm wins contract from BlaBla Connect - 20-Jun-2018 12:51
Infosys opens digital center of excellence in France - 20-Jun-2018 10:13
Shreyas Shipping & Logistics takes delivery of vessel 'M.V. SSL Krishna' - 20-Jun-2018 10:09
ABB partners with Cochin Shipyard and Shipping Corporation of India - 20-Jun-2018 09:57
ABB partners with Cochin Shipyard and Shipping Corporation of India - 20-Jun-2018 09:57
Kansai Nerolac to enter into Bangladesh bv acquiring equity stake in RAK Paints - 20-Jun-2018 09:51
Cipla receives final approval for generic Sustiva - 19-Jun-2018 16:22
Dr. Reddy's Lab launches Levetiracetam in NaCl injection - 19-Jun-2018 12:23
Zydus Cadila receives tentative approval for Tadalafil tablets - 19-Jun-2018 12:22
Tata Power partners IDFC Bank for digitized solution in Mumbai - 19-Jun-2018 11:21
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer